Programmed death ligand 1 (PD-L1) is a critical immune checkpoint protein, representing an important target in cancer immunotherapy, as the overexpression of PD-L1 on the surface of tumor cells is a common immune evasion strategy of cancer cells [1]. This evidence concerns the gene CD274 and neoplasm.